IgE-Related Chronic Diseases and Anti-IgE-Based Treatments
Journal of Immunology Research, 2016 IgE is an immunoglobulin that plays a central role in acute allergic reactions and chronic inflammatory allergic diseases. The development of a drug able to neutralize this antibody represents a breakthrough in the treatment of inflammatory pathologies ...
Arnau Navinés-Ferrer +3 more
doaj +1 more source
Long-Term Successful Treatment of Indolent Systemic Mastocytosis With Omalizumab [PDF]
, 2021 Samuel L Weiss
openalex +1 more source
Allergy, EarlyView.Appropriate treatment escalation improves CSU disease control. However, only about a quarter of patients achieve a complete response, the main goal of CSU treatment. Approximately one‐third of patients clinically eligible for escalation (UCT < 12) do not receive guideline‐recommended treatment escalation and remain symptomatic on their current ...
Pavel Kolkhir +25 more
wiley +1 more source
Long-Term Omalizumab use in the Treatment of Exercise-Induced Anaphylaxis
Allergy & Rhinology, 2017 Reported is a case of a 39-year-old male who was diagnosed with exercise-induced anaphylaxis (EIA). He was initially treated prophylactically with fexofenadine, montelukast, and ranitidine. He also used an epinephrine autoinjector as needed.
Mark R. Peterson D.O. +1 more
doaj +1 more source
Outcomes of off-label drug uses in hospitals: a multicentric prospective study [PDF]
, 2015 Purpose: The study aims to assess the clinical evidence, outcome and cost of off-label use of medicines in the hospital setting. Methods: A multicentric prospective cohort study of patients treated with off-label medicines was carried out in five ...
Agustí, Antonia +12 more
core +1 more source
Clinical &Experimental Allergy, EarlyView.Real‐world patients with severe eosinophilic asthma treated with benralizumab showed early and sustained improvements in symptoms. Clinically meaningful improvements began as early as one week after benralizumab initiation, regardless of previous biologic use, and further improved over the following year.
Erika Penz +12 more
wiley +1 more source
Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study [PDF]
, 2016 BACKGROUND: Omalizumab (Xolair®), a recombinant monoclonal anti-IgE antibody, has demonstrated efficacy in clinical trials conducted in patients with moderate to severe persistent allergic asthma. We aimed to investigate the efficacy, discontinuation and
Chien-Da Huang +3 more
core +1 more source
How to evaluate a patient's response to anti-IgE
European Respiratory Review, 2007 Omalizumab, an anti-immunoglobulin E antibody, is indicated in the European Union (EU) as add-on therapy for patients with severe persistent allergic asthma whose symptoms persist, despite receiving optimised treatment with high-dose inhaled ...
S. T. Holgate
doaj
Induced sputum versus exhaled nitric oxide for the evaluation of airway inflammation in allergic paediatric asthma patients treated with omalizumab [PDF]
, 2013 Our purpose is to determine the inflammatory changes in the airways of allergic paediatric asthma patients treated with omalizumab, measured by the percentage ofEl nostre objectiu és determinar els canvis inflamatoris en la via aèria de pacients ...
Domingo Miró, Xavier +2 more
core +1 more source
Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective [PDF]
, 2021 Catherine King +5 more
openalex +1 more source